

Resource Summary Report

Generated by [dkNET](#) on Aug 14, 2026

NK-92

RRID:CVCL_2142

Type: Cell Line

Proper Citation

RRID:CVCL_2142

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2142

Proper Citation: RRID:CVCL_2142

Description: Cell line NK-92 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Natural killer cell lymphoblastic leukemia/lymphoma

Defining Citation: [PMID:8152260](#), [PMID:9118301](#), [PMID:9573023](#), [PMID:10365666](#), [PMID:10803505](#), [PMID:11454312](#), [PMID:12850795](#), [PMID:16827800](#), [PMID:18424763](#), [PMID:19194464](#), [PMID:20454443](#), [PMID:21052088](#), [PMID:21570725](#), [PMID:25586472](#), [PMID:26559813](#), [PMID:30054012](#), [PMID:31126350](#), [PMID:31160637](#), [PMID:34349345](#), [PMID:36610812](#)

Comments: Caution: This cell line is exclusively owned and controlled by NantKwest, Inc. NantKwest and its affiliate, Brink Biologics, Inc. are the sole authorized distributors for both commercial and non-commercial research requestors. There are no other authorized commercial and noncommercial suppliers of NK-92 cells. Contact NantKwest and Brink Biologics for information concerning current inventory and cell line use and support., Miscellaneous: Neukoplast is used as a trademark to refer to NK-92 cells that are available for non-human research applications while aNK is used as a trademark to refer to cells from the cGMP-grade NK-92 cell-line that is in use for therapeutic human testing., Characteristics: Does not express FCGR3A/CD16., Characteristics: IL2 dependent., Characteristics: Laboratory use as a standard cell line for antibody-dependent cell-mediated cytotoxicity (ADCC) testing. Also being developed for cellular adoptive immunotherapy for cancers and viral infections., Population: Caucasian., Part of: LL-100 blood cancer cell line panel., Group: Patented cell line.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: NK-92

Synonyms: NK92, Natural Killer-92, NK-92.05, Neukoplast, aNK

Cross References: BTO:BTO_0003287, CLO:CLO_0008177, EFO:EFO_0022517, AddexBio:C0003026/NA, ArrayExpress:E-MTAB-7721, ArrayExpress:E-MTAB-7722, ATCC:CRL-2407, BCRC:60414, BioSample:SAMN03471836, CCRID:4201HUM-CCTCC00052, CCTCC:GDC0052, Cell_Model_Passport:SIDM01143, Cosmic:1534874, Cosmic:1542071, Cosmic:2025326, Cosmic:2390215, Cosmic:2785204, DSMZ:ACC-488, DSMZCellDive:ACC-488, GEO:GSM472001, IPD-IMGT/HLA:13674, Lonza:1093, Wikidata:Q17149636

ID: CVCL_2142

Record Creation Time: 20220427T221344+0000

Record Last Update: 20260809T002423+0000

Ratings and Alerts

No rating or validation information has been found for NK-92.

Warning: Discontinued: ATCC; PTA-6670

Caution: This cell line is exclusively owned and controlled by NantKwest, Inc. NantKwest and its affiliate, Brink Biologics, Inc. are the sole authorized distributors for both commercial and non-commercial research requestors. There are no other authorized commercial and noncommercial suppliers of NK-92 cells. Contact NantKwest and Brink Biologics for information concerning current inventory and cell line use and support., Miscellaneous: Neukoplast is used as a trademark to refer to NK-92 cells that are available for non-human research applications while aNK is used as a trademark to refer to cells from the cGMP-grade NK-92 cell-line that is in use for therapeutic human testing., Characteristics: Does not express FCGR3A/CD16., Characteristics: IL2 dependent., Characteristics: Laboratory use as a standard cell line for antibody-dependent cell-mediated cytotoxicity (ADCC) testing. Also being developed for cellular adoptive immunotherapy for cancers and viral infections., Population: Caucasian., Part of: LL-100 blood cancer cell line panel., Group: Patented cell line. **Warning:** Discontinued: BCRC; 60414

Caution: This cell line is exclusively owned and controlled by NantKwest, Inc. NantKwest and its affiliate, Brink Biologics, Inc. are the sole authorized distributors for both commercial and non-commercial research requestors. There are no other authorized commercial and noncommercial suppliers of NK-92 cells. Contact NantKwest and Brink Biologics for information concerning current inventory and cell line use and support., Miscellaneous: Neukoplast is used as a trademark to refer to NK-92 cells that are available for non-human research applications while aNK is used as a trademark to refer to cells from the cGMP-grade NK-92 cell-line that is in use for therapeutic human testing., Characteristics: Does not express FCGR3A/CD16., Characteristics: IL2 dependent., Characteristics: Laboratory use as a standard cell line for antibody-dependent cell-mediated cytotoxicity (ADCC) testing. Also being developed for cellular adoptive immunotherapy for cancers and viral infections., Population: Caucasian., Part of: LL-100

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 422 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Munoz MA, et al. (2026) NK cell dysfunction and interferon- γ production underlie autoinflammation in mevalonate kinase deficiency. *Immunity*, 59(6), 1726.

B γ dzi γ ska A, et al. (2026) The p53 tumor suppressor modulates the expression of proteins that control natural killer cell activity. *Cell communication and signaling : CCS*, 24(1).

Huo Y, et al. (2026) FOSL1 Orchestrates Epigenetic Reprogramming of Anaplastic Thyroid Cancer and Suppresses NK Cell-Mediated Antitumor Immunity. *Cancer research*, 86(9), 2184.

Hu X, et al. (2026) Immune gene diversity and STING1 variants in shaping cancer immunity across different genetic ancestry populations. *Cell reports*, 45(2), 116882.

Kim D, et al. (2026) Bioprinted Tumor Microenvironment Models Reveal Immune Evasion and Guide CAR-NK Therapeutic Strategies. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 13(36), e21188.

Ianevski A, et al. (2026) Multiomics Profiling of T-cell Leukemia and Lymphoma Enables Targeted Therapeutic Discovery. *Cancer research*, 86(2), 295.

Zhou J, et al. (2026) Orosomucoid 2 promotes colorectal cancer liver metastasis by suppressing natural killer cell-mediated antitumor immunity by remodeling the serine and one-carbon metabolism pathway. *Molecular cancer*, 25(1).

Calescibetta A, et al. (2026) Combining lenalidomide with IL-2 family of cytokines enhances activating receptor and perforin/granzyme expression in NK cells. *PloS one*, 21(3), e0344471.

Ghaffari S, et al. (2026) A fully human pan VL9 HLA-E TCRm antibody enables functional dissection of HLA-E biology and checkpoint signaling. *iScience*, 29(5), 115669.

Tao G, et al. (2026) Radiation-induced MYB reduction unleashes TIM-3 expression in NK cells to attenuate antitumor immunity in colorectal cancer. *Journal of translational medicine*, 24(1).

Zhou Y, et al. (2025) Chronic ER Stress Triggers Cell-Surface Chaperones as the Therapeutic Targets of CAR Cells in Acute Myeloid Leukemia. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, e11573.

Cai HM, et al. (2025) DDX3X mutation and Epstein-Barr virus cooperate to induce R-loop-dependent oncogenesis. *Cell reports*, 44(9), 116237.

Gao T, et al. (2025) Molecular basis of $\alpha 2$ integrin activation by talin unveils subunit-specific mechanisms of integrin signaling. *Cell reports*, 44(5), 115607.

Phung SK, et al. (2025) A PSMA-Targeted Tri-Specific Killer Engager Enhances NK Cell Cytotoxicity against Prostate Cancer. *Cancer immunology research*, 13(2), 258.

Stransky N, et al. (2025) Chimeric antigen receptor NK-92 cell function is modulated by HLA class I expression of target cells. *iScience*, 28(5), 112523.

Maskalenko NA, et al. (2025) The Fc γ RIIIA (CD16) L48-H/R Polymorphism Enhances NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity by Promoting Serial Killing. *Cancer immunology research*, 13(3), 417.

Decalf J, et al. (2025) Effectorless Fc-fusion improves FLT3L drug-like properties for cancer immunotherapy combinations. *EBioMedicine*, 118, 105822.

Hai Y, et al. (2025) An immunometabolic prodrug strategy overcomes DHODH inhibitor resistance in refractory melanoma. *Journal of experimental & clinical cancer research : CR*, 44(1), 306.

Ning K, et al. (2025) Non-destructive in situ monitoring of structural changes of 3D tumor spheroids during the formation, migration, and fusion process. *eLife*, 13.

B $\acute{e}$ dzi $\acute{s}$ ka A, et al. (2025) The puzzling regulation of the interferon signaling system by the p53 tumor suppressor protein. *Cellular and molecular life sciences : CMLS*, 82(1), 233.